Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
2017 · New England Journal of Medicine · 5,655 citations
https://doi.org/10.1056/nejmoa1707447
E
Eric D. Jacobsen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
358
Papers
18.2K
Citations
54
h-index
121
i10-index
Eric D. Jacobsen is an academic researcher from Boston University. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & CAR-T cell therapy research. The author has an h-index of 54, co-authored 305 publications.
ORCID: 0000-0003-3014-0023Papers by this author
worksConsensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
2018 · Blood · 584 citations
https://doi.org/10.1182/blood-2018-03-839753
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
2017 · The Lancet · 433 citations
https://doi.org/10.1016/s0140-6736(17)33108-2
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
2018 · Nature Communications · 111 citations
https://doi.org/10.1038/s41467-018-04356-9
Rosai–Dorfman Disease with Activating <i>KRAS</i> Mutation — Response to Cobimetinib
2017 · New England Journal of Medicine · 109 citations
https://doi.org/10.1056/nejmc1713676
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
2021 · Journal of the National Comprehensive Cancer Network · 68 citations
https://doi.org/10.6004/jnccn.2021.0053
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat